Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden-Reference-Cited by-同舟云学术

Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden

Published:2016-04-07 Issue:5 Volume:94 Page:441-448
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:Acta Ophthalmol

Author:

Panchmatia Hemangi R.¹,Clements Karen M.¹,Hulbert Erin²,Eriksson Marianne³,Wittrup-Jensen Kim⁴,Nilsson Jonas⁵,Weinstein Milton C.⁶⁷

Affiliation:

1. Optum; Waltham Massachusetts USA

2. Optum; Eden Prairie Minnesota USA

3. Bayer AB; Solna Sweden

4. Bayer Pharma AG; Berlin Germany

5. Optum; Stockholm Sweden

6. Harvard School of Public Health; Boston Massachusetts USA

7. Harvard T.H. Chan School of Public Health; Boston Massachusetts USA

Funder

Bayer Pharma AG

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Reference38 articles.

1. Akademiska sjukhuset 2013a Prislista för utomlänssjukvård 2013. Uppsala, Sweden http://svnuppsalaorebro.se/3-styrande/prislista.html

2. Akademiska sjukhuset 2013b Prislista för vård av utomlänspatienter samt utlandspatienter inom EU 2015, Diagnostik-,akut-,anestesi- och teknikdivisionen. Uppsala, Sweden http://svnuppsalaorebro.se/3-styrande/prislistor/2015/Prislistor_Uppsala_2015_07.pdf

3. Bayer 2011 Summary Report for the studies VIEW 1 and VIEW 2 Two randomized, double masked, active controlled, phase 3 studies of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macular degeneration (AMD)

4. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration;Boyer;Ophthalmology,2009

5. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration;Brown;Ophthalmology,2007

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis;Journal of Managed Care & Specialty Pharmacy;2022-12

2. Different effects of anti-VEGF drugs (Ranibizumab, Aflibercept, Conbercept) on autophagy and its effect on neovascularization in RF/6A cells;Microvascular Research;2021-11

3. Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration;Graefe's Archive for Clinical and Experimental Ophthalmology;2021-10-13

4. Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration;Annals of Translational Medicine;2020-08

5. A Systematic Review of Economic Studies Evaluating Ophthalmic Drugs: An Analysis of the Health-state Utilities;Ophthalmic Epidemiology;2020-07-21